

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI404917

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Syed Asfar Mateen	04/25/2022
Praveen Kumar Mididoddi	04/25/2022
Shailly Mehrotra	04/29/2022
Susan Elizabeth Shoaf	04/25/2022
Salin Gupta	04/28/2022
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
<b>Street Address:</b>	2440 Research Blvd.
<b>City:</b>	Rockville
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20850
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	18427459
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	3124740448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3124746820
<b>Email:</b>	docket@marshallip.com
<b>Correspondent Name:</b>	Marshall Gerstein & Borun LLP
<b>Address Line 1:</b>	233 South Wacker Drive
<b>Address Line 2:</b>	Suite 6300
<b>Address Line 4:</b>	Chicago, ILLINOIS 60606
<b>ATTORNEY DOCKET NUMBER:</b>	33403/56333C
<b>NAME OF SUBMITTER:</b>	Jennie Mackowiak
<b>SIGNATURE:</b>	Jennie Mackowiak
<b>DATE SIGNED:</b>	08/02/2024
<b>Total Attachments: 20</b>	

source=Inventors to Otsuka#page1.tiff  
source=Inventors to Otsuka#page2.tiff  
source=Inventors to Otsuka#page3.tiff  
source=Inventors to Otsuka#page4.tiff  
source=Inventors to Otsuka#page5.tiff  
source=Inventors to Otsuka#page6.tiff  
source=Inventors to Otsuka#page7.tiff  
source=Inventors to Otsuka#page8.tiff  
source=Inventors to Otsuka#page9.tiff  
source=Inventors to Otsuka#page10.tiff  
source=Inventors to Otsuka#page11.tiff  
source=Inventors to Otsuka#page12.tiff  
source=Inventors to Otsuka#page13.tiff  
source=Inventors to Otsuka#page14.tiff  
source=Inventors to Otsuka#page15.tiff  
source=Inventors to Otsuka#page16.tiff  
source=Inventors to Otsuka#page17.tiff  
source=Inventors to Otsuka#page18.tiff  
source=Inventors to Otsuka#page19.tiff  
source=Inventors to Otsuka#page20.tiff

## ASSIGNMENT

WHEREAS I/we,

**Syed Asfar Mateen** of **Robbinsville, NJ, United States;**

**Praveen Kumar Mididoddi** of **Pennington, NJ, United States;**

**Shailly Mehrotra** of **Acton, MA, United States;**

**Susan Elizabeth Shoaf** of **Silver Spring, MD, United States; and**

**Salin Gupta** of **Bridgewater, NJ, United States;**

collectively ("Assignor"), have filed patent applications identified as

US Serial No. **17/677,726**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**"; and

PCT Serial No. **PCT/JP2022/007314**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**";

AND WHEREAS, **Otsuka Pharmaceutical Development & Commercialization, Inc.** ("Assignee"), a corporation organized and existing under the laws of the **Delaware**, with a principal place of business at **2440 Research Blvd., Rockville, MD 20850, United States** is desirous of acquiring the entire right, title and interest in and to the above-referenced application(s), any and all inventions or improvements described in whole or in part therein, and in and to any and all Letters Patent and certificates of the United States, foreign countries, and all regions worldwide which may be obtained therefor (collectively hereinafter referred to as "Invention"):

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Assignor has assigned, transferred, and conveyed, and/or do hereby assign, transfer, and convey to Assignee the entire right, title, and interest in and to said application(s) and said Invention, and all the rights, privileges, and benefits therein, including any

and all rights, privileges, and benefits under the Paris Convention for the Protection of Industrial Property, including the right to claim priority based on said patent application(s), and under any and all Letters Patent or patents which may be granted therefor, and all right, title, and interest in and to every patent application filed or to be filed on or in relation wholly or partly to said Invention in any country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said patent application(s), and all the rights, privileges, and benefits therein, including the right to claim priority based on said patent application(s), and all right, title, and interest in and to any and all patents which may issue thereon, and any reissues, reexaminations, pipelines, extensions, supplementary protection certificates, and governmental exclusivity rights extending therefrom.

AND Assignor hereby authorizes Assignee, its successors, assigns, or legal representatives to file in any and all countries patent applications respecting said Invention, whether wholly or in part, in my/our name or its or their own name(s).

AND Assignor hereby represents and warrants that the Assignor has the right and power to convey the entire interest herein assigned, and that the Assignor has not made and will not make any other assignment that conflicts with this Assignment.

AND Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said Invention, said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said Invention or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said Invention, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

AND Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as assignee of the entire right, title and interest, any and all applications and Letters Patent for said Invention or any part of it, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application(s) aforesaid, in accordance with the terms of this assignment.

THE effective date of this ASSIGNMENT shall be the earliest filing date of the above-reference patent application(s).

Signed by:

Signature: 

Date: 25 APR 2022

Name: Syed Asfar Mateen

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Praveen Kumar Mididoddi

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Shailly Mehrotra

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Susan Elizabeth Shoaf

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Salin Gupta

Signed by and on behalf of the ASSIGNEE:

ASSIGNEE: Otsuka Pharmaceutical Development & Commercialization, Inc.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Karen R. Gally

Title: Vice President and General Counsel

**ASSIGNMENT**

WHEREAS I/we,

<b>Syed Asfar Mateen</b>	of	<b>Robbinsville, NJ, United States;</b>
<b>Praveen Kumar Mididoddi</b>	of	<b>Pennington, NJ, United States;</b>
<b>Shailly Mehrotra</b>	of	<b>Acton, MA, United States;</b>
<b>Susan Elizabeth Shoaf</b>	of	<b>Silver Spring, MD, United States; and</b>
<b>Salin Gupta</b>	of	<b>Bridgewater, NJ, United States;</b>

collectively ("Assignor"), have filed patent applications identified as

US Serial No. 17/677,726, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**"; and

PCT Serial No. **PCT/JP2022/007314**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**";

AND WHEREAS, **Otsuka Pharmaceutical Development & Commercialization, Inc.** ("Assignee"), a corporation organized and existing under the laws of the **Delaware**, with a principal place of business at **2440 Research Blvd., Rockville, MD 20850, United States** is desirous of acquiring the entire right, title and interest in and to the above-referenced application(s), any and all inventions or improvements described in whole or in part therein, and in and to any and all Letters Patent and certificates of the United States, foreign countries, and all regions worldwide which may be obtained therefor (collectively hereinafter referred to as "Invention"):

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Assignor has assigned, transferred, and conveyed, and/or do hereby assign, transfer, and convey to Assignee the entire right, title, and interest in and to said application(s) and said Invention, and all the rights, privileges, and benefits therein, including any

and all rights, privileges, and benefits under the Paris Convention for the Protection of Industrial Property, including the right to claim priority based on said patent application(s), and under any and all Letters Patent or patents which may be granted therefor, and all right, title, and interest in and to every patent application filed or to be filed on or in relation wholly or partly to said Invention in any country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said patent application(s), and all the rights, privileges, and benefits therein, including the right to claim priority based on said patent application(s), and all right, title, and interest in and to any and all patents which may issue thereon, and any reissues, reexaminations, pipelines, extensions, supplementary protection certificates, and governmental exclusivity rights extending therefrom.

AND Assignor hereby authorizes Assignee, its successors, assigns, or legal representatives to file in any and all countries patent applications respecting said Invention, whether wholly or in part, in my/our name or its or their own name(s).

AND Assignor hereby represents and warrants that the Assignor has the right and power to convey the entire interest herein assigned, and that the Assignor has not made and will not make any other assignment that conflicts with this Assignment.

AND Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said Invention, said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said Invention or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said Invention, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.



AND Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as assignee of the entire right, title and interest, any and all applications and Letters Patent for said Invention or any part of it, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application(s) aforesaid, in accordance with the terms of this assignment.

THE effective date of this ASSIGNMENT shall be the earliest filing date of the above-reference patent application(s).


Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Syed Asfar Mateen

Signed by:

Signature:  \_\_\_\_\_

Date: 25 APR 2022

Name: Praveen Kumar Mididoddi

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Shailly Mehrotra

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Susan Elizabeth Shoaf

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Salin Gupta

Signed by and on behalf of the ASSIGNEE:

ASSIGNEE: Otsuka Pharmaceutical Development & Commercialization, Inc.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Karen R. Gally

Title: Vice President and General Counsel

**ASSIGNMENT**

WHEREAS I/we,

**Syed Asfar Mateen** of **Robbinsville, NJ, United States;**

**Praveen Kumar Mididoddi** of **Pennington, NJ, United States;**

**Shailly Mehrotra** of **Acton, MA, United States;**

**Susan Elizabeth Shoaf** of **Silver Spring, MD, United States; and**

**Salin Gupta** of **Bridgewater, NJ, United States;**

collectively ("Assignor"), have filed patent applications identified as

US Serial No. 17/677,726, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**"; and

PCT Serial No. **PCT/JP2022/007314**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**";

AND WHEREAS, **Otsuka Pharmaceutical Development & Commercialization, Inc.** ("Assignee"), a corporation organized and existing under the laws of the **Delaware**, with a principal place of business at **2440 Research Blvd., Rockville, MD 20850, United States** is desirous of acquiring the entire right, title and interest in and to the above-referenced application(s), any and all inventions or improvements described in whole or in part therein, and in and to any and all Letters Patent and certificates of the United States, foreign countries, and all regions worldwide which may be obtained therefor (collectively hereinafter referred to as "Invention"):

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Assignor has assigned, transferred, and conveyed, and/or do hereby assign, transfer, and convey to Assignee the entire right, title, and interest in and to said application(s) and said Invention, and all the rights, privileges, and benefits therein, including any

and all rights, privileges, and benefits under the Paris Convention for the Protection of Industrial Property, including the right to claim priority based on said patent application(s), and under any and all Letters Patent or patents which may be granted therefor, and all right, title, and interest in and to every patent application filed or to be filed on or in relation wholly or partly to said Invention in any country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said patent application(s), and all the rights, privileges, and benefits therein, including the right to claim priority based on said patent application(s), and all right, title, and interest in and to any and all patents which may issue thereon, and any reissues, reexaminations, pipelines, extensions, supplementary protection certificates, and governmental exclusivity rights extending therefrom.

AND Assignor hereby authorizes Assignee, its successors, assigns, or legal representatives to file in any and all countries patent applications respecting said Invention, whether wholly or in part, in my/our name or its or their own name(s).

AND Assignor hereby represents and warrants that the Assignor has the right and power to convey the entire interest herein assigned, and that the Assignor has not made and will not make any other assignment that conflicts with this Assignment.

AND Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said Invention, said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said Invention or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said Invention, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

AND Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as assignee of the entire right, title and interest, any and all applications and Letters Patent for said Invention or any part of it, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application(s) aforesaid, in accordance with the terms of this assignment.

THE effective date of this ASSIGNMENT shall be the earliest filing date of the above-reference patent application(s).

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Syed Asfar Mateen

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Praveen Kumar Mididoddi

Signed by:

Signature: Shailly

Date: April 29, 2022

Name: Shailly Mehrotra

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Susan Elizabeth Shoaf

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Salin Gupta

Signed by and on behalf of the ASSIGNEE:

ASSIGNEE: Otsuka Pharmaceutical Development & Commercialization, Inc.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Karen R. Gally

Title: Vice President and General Counsel

### **ASSIGNMENT**

WHEREAS I/we,

**Syed Asfar Mateen** of **Robbinsville, NJ, United States;**

**Praveen Kumar Mididoddi** of **Pennington, NJ, United States;**

**Shailly Mehrotra** of **Acton, MA, United States;**

**Susan Elizabeth Shoaf** of **Silver Spring, MD, United States;** and

**Salin Gupta** of **Bridgewater, NJ, United States;**

collectively ("Assignor"), have filed patent applications identified as

US Serial No. 17/677,726, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**"; and

PCT Serial No. **PCT/JP2022/007314**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**";

AND WHEREAS, **Otsuka Pharmaceutical Development & Commercialization, Inc.** ("Assignee"), a corporation organized and existing under the laws of the **Delaware**, with a principal place of business at **2440 Research Blvd., Rockville, MD 20850, United States** is desirous of acquiring the entire right, title and interest in and to the above-referenced application(s), any and all inventions or improvements described in whole or in part therein, and in and to any and all Letters Patent and certificates of the United States, foreign countries, and all regions worldwide which may be obtained therefor (collectively hereinafter referred to as "Invention");

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Assignor has assigned, transferred, and conveyed, and/or do hereby assign, transfer, and convey to Assignee the entire right, title, and interest in and to said

application(s) and said Invention, and all the rights, privileges, and benefits therein, including any and all rights, privileges, and benefits under the Paris Convention for the Protection of Industrial Property, including the right to claim priority based on said patent application(s), and under any and all Letters Patent or patents which may be granted therefor, and all right, title, and interest in and to every patent application filed or to be filed on or in relation wholly or partly to said Invention in any country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said patent application(s), and all the rights, privileges, and benefits therein, including the right to claim priority based on said patent application(s), and all right, title, and interest in and to any and all patents which may issue thereon, and any reissues, reexaminations, pipelines, extensions, supplementary protection certificates, and governmental exclusivity rights extending therefrom.

AND Assignor hereby authorizes Assignee, its successors, assigns, or legal representatives to file in any and all countries patent applications respecting said Invention, whether wholly or in part, in my/our name or its or their own name(s).

AND Assignor hereby represents and warrants that the Assignor has the right and power to convey the entire interest herein assigned, and that the Assignor has not made and will not make any other assignment that conflicts with this Assignment.

AND Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said Invention, said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said Invention or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said Invention, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.



AND Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as assignee of the entire right, title and interest, any and all applications and Letters Patent for said Invention or any part of it, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application(s) aforesaid, in accordance with the terms of this assignment.

THE effective date of this ASSIGNMENT shall be the earliest filing date of the above-reference patent application(s).

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Syed Asfar Mateen

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Praveen Kumar Mididoddi

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Shailly Mehrotra

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Susan Elizabeth Shoaf

Signed by:

Signature: Salin

Date: 4/28/2022

Name: Salin Gupta

Signed by and on behalf of the ASSIGNEE:

ASSIGNEE: Otsuka Pharmaceutical Development & Commercialization, Inc.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Karen R. Gally

Title: Vice President and General Counsel

**ASSIGNMENT**

WHEREAS I/we,

**Syed Asfar Mateen** of **Robbinsville, NJ, United States;**

**Praveen Kumar Mididoddi** of **Pennington, NJ, United States;**

**Shailly Mehrotra** of **Acton, MA, United States;**

**Susan Elizabeth Shoaf** of **Silver Spring, MD, United States; and**

**Salin Gupta** of **Bridgewater, NJ, United States;**

collectively ("Assignor"), have filed patent applications identified as

US Serial No. 17/677,726, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**"; and

PCT Serial No. **PCT/JP2022/007314**, filed **February 22, 2022**, entitled "**CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME**";

AND WHEREAS, **Otsuka Pharmaceutical Development & Commercialization, Inc.** ("Assignee"), a corporation organized and existing under the laws of the **Delaware**, with a principal place of business at **2440 Research Blvd., Rockville, MD 20850, United States** is desirous of acquiring the entire right, title and interest in and to the above-referenced application(s), any and all inventions or improvements described in whole or in part therein, and in and to any and all Letters Patent and certificates of the United States, foreign countries, and all regions worldwide which may be obtained therefor (collectively hereinafter referred to as "Invention"):

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Assignor has assigned, transferred, and conveyed, and/or do hereby assign, transfer, and convey to Assignee the entire right, title, and interest in and to said application(s) and said Invention, and all the rights, privileges, and benefits therein, including any

and all rights, privileges, and benefits under the Paris Convention for the Protection of Industrial Property, including the right to claim priority based on said patent application(s), and under any and all Letters Patent or patents which may be granted therefor, and all right, title, and interest in and to every patent application filed or to be filed on or in relation wholly or partly to said Invention in any country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said patent application(s), and all the rights, privileges, and benefits therein, including the right to claim priority based on said patent application(s), and all right, title, and interest in and to any and all patents which may issue thereon, and any reissues, reexaminations, pipelines, extensions, supplementary protection certificates, and governmental exclusivity rights extending therefrom.

AND Assignor hereby authorizes Assignee, its successors, assigns, or legal representatives to file in any and all countries patent applications respecting said Invention, whether wholly or in part, in my/our name or its or their own name(s).

AND Assignor hereby represents and warrants that the Assignor has the right and power to convey the entire interest herein assigned, and that the Assignor has not made and will not make any other assignment that conflicts with this Assignment.

AND Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said Invention, said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said Invention or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said Invention, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

AND Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as assignee of the entire right, title and interest, any and all applications and Letters Patent for said Invention or any part of it, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application(s) aforesaid, in accordance with the terms of this assignment.

THE effective date of this ASSIGNMENT shall be the earliest filing date of the above-reference patent application(s).

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Syed Asfar Mateen

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Praveen Kumar Mididoddi

Signed by:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name: Shailly Mehrotra

Signed by:

Signature: Susan Elizabeth Shoaf Date: Apr 25, 2022

Name: Susan Elizabeth Shoaf

Signed by:

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name: Salin Gupta

Signed by and on behalf of the ASSIGNEE:

ASSIGNEE: Otsuka Pharmaceutical Development & Commercialization, Inc.

Signature: Karen R. Gally Date: 25 April 2022

Name: Karen R. Gally

Title: Vice President and General Counsel